Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

This study is testing a combination of four drugs — blinatumomab, methotrexate, cytarabine, and ponatinib — to treat a form of acute lymphoblastic leukemia (blood cancer) that is linked to a specific genetic change called the Philadelphia chromosome (BCR-ABL), including newly diagnosed patients and those whose cancer has returned or stopped responding to treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of Philadelphia chromosome-positive (BCR-ABL+) ALL, or with leukemia that has relapsed or become resistant to previous treatment - You are in reasonably good physical condition (ECOG 0–2) - Your liver, kidney, and heart function meet the required levels **You may NOT be eligible if...** - You have a history of pancreatitis or alcohol abuse - You have uncontrolled high blood pressure, recent heart attack or stroke, or severe heart failure - You have active HIV, hepatitis B, or hepatitis C - You have had a significant seizure disorder or serious brain condition (not including active brain leukemia, which is allowed) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.